Thus, efforts to block CTLA-4 resulted in the advent of the monoclonal anti-CTLA-4 antibody, Ipilimumab, which was approved to be used as a checkpoint inhibitor for the treatment of melanoma (8, 9). Here, CTLA4 is linked to melanoma.